Can I take part?

Eligibility criteria

The cosMOG study is looking for about 100 people worldwide who:

  • Are between 18 and 89 years old
  • Have relapsing MOG‑AD with at least one relapse (after the initial attack)
    in the last 12 months
  • Have at least one of the following:

Optic neuritis

Symptoms may include:
Eye pain, blurred vision, potential complete loss of vision

Transverse myelitis

Symptoms may include:
Leg and/or arm weakness, sensory problems, bladder dysfunction, back pain

Acute disseminated encephalomyelitis (ADEM) or MOG‑AD encephalitis

Symptoms may include:
Nausea and vomiting, headache, confusion, seizures, unsteadiness or inability to walk, problems with vision

There are additional eligibility criteria you need to meet to be able to participate in the study. The study team will discuss these with you.

Find your nearest study site

To find out if this study could be right for you, please contact the study site nearest you. If there are no locations near you, please check again later, as a site may become available in the future.

All current study sites

About the cosMOG study

The cosMOG study aims to understand how well-tolerated and effective an investigational drug called rozanolixizumab is in people with MOG‑AD. The investigational drug will be given weekly as an infusion under the skin.

With no approved treatment options for MOG‑AD, we understand that your treatment journey may not have been an easy one. Clinical research studies, also called clinical trials, are a necessary and vital step toward understanding rare diseases such as MOG‑AD and how to treat them.

With your help, the cosMOG study will evaluate if an investigational drug can prolong the time between relapses for people with this condition.

Learn more about this study

Are you eligible?

You may be eligible to take part in the cosMOG study if you (among other things):

  • Are between 18 and 89 years old
  • Have relapsing MOG‑AD with at least one relapse in the last 12 months
  • Have at least one of the following:
  • Optic neuritis
  • Transverse myelitis
  • Acute disseminated encephalomyelitis (ADEM) or MOG‑AD encephalitis
Find a study site near you

This page is for healthcare providers only.

Are you a healthcare provider?


You are about to leave You will be redirected to outbound url.
Do you want to continue?


The content you are trying to access is no longer available.


Copy page link

Send from your email account

Navigate to default email client